Myelofibrosis Clinical Trial
— ALLO-BATOfficial title:
A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)
The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis. This will be done by asking participants to choose the treatment that they prefer to receive (HCT or BAT) and then comparing the outcomes of the participants in both treatment groups.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | February 5, 2026 |
Est. primary completion date | August 5, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: Recruitment Part: - Documented diagnosis of pre-fibrotic primary myelofibrosis (pre-fibrotic PMF), overt PMF, post-polycythemia MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF) confirmed by bone marrow biopsy - Have been tested or have results available for phenotypic driver mutations (JAK2/CALR/MPL) and high molecular risk (HMR) mutations using a broad myeloid malignancies targeted gene panel. - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Able to provide informed consent - Adequate organ function - Donor search initiated or patient is agreeable to donor search - Meet the definition/criteria for high-risk myelofibrosis Study Arm Allocation: - Grade of fibrosis on bone marrow biopsy available according to World Health Organization (WHO) criteria - Results available for phenotypic driver mutations (JAK2/CALR/MPL) and targeted sequencing results using a broad myeloid malignancy panel with a minimal requirement to include results on High molecular risk (HMR) mutations such as ASXL1/EZH2/IDH1/IDH2/SRSF2/U2AF1/TP53 - ECOG performance status 0-2 - Adequate organ function - Information on donor search and donor type available Exclusion Criteria: Recruitment Part: - Blasts in peripheral blood or bone marrow =10% - For patients already on ruxolitinib at study entry, and meet the criteria of ruxolitinib failure - Previous history of transformation to blast phase or acute myeloid leukemia - Received allogeneic stem cell transplant for myeloproliferative neoplasm - Presence of an active uncontrolled infection - Myocardial infarction in the preceding 3 months - Active hepatitis A, B or C - Known human immunodeficiency virus (HIV) positive - History of active malignancy in the previous 2 years, except basal cell carcinoma or squamous cell carcinoma of skin or stage 0 cervical cancer - Any psychiatric illness or social circumstances or significant co-morbid conditions that will prevent patient from proceeding to allogeneic hematopoietic cell transplantation. - Pregnant or breastfeeding women Study Arm Allocation: - Blasts in peripheral blood or bone marrow =10% - Meet the criteria of ruxolitinib failure - Presence of an active uncontrolled infection - Myocardial infarction in the preceding 3 months - Active hepatitis A, B or C - Known HIV positive - History of active malignancy in the previous 2 years, except basal cell carcinoma or squamous cell carcinoma of skin or stage 0 cervical cancer - Pregnant or breastfeeding women - Any psychiatric illness or social circumstances or significant co-morbid conditions that will prevent patient from proceeding to allogeneic hematopoietic cell transplantation. - Time between registration and allocation of study arm >24 weeks |
Country | Name | City | State |
---|---|---|---|
Canada | Tom Baker Cancer Centre | Calgary | Alberta |
Canada | Cross Cancer Institute | Edmonton | Alberta |
Canada | Nova Scotia Health Authority | Halifax | Nova Scotia |
Canada | Princess Margaret Cancer Centre | Toronto | Ontario |
Canada | St. Paul's Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients allocated to hematopoietic stem cell transplantation (HCT) | 5 years | ||
Primary | Number of patients allocated to best available non-transplant therapies (BAT) | 5 years | ||
Primary | Overall survival rate of patients who receive hematopoietic stem cell transplantation (HCT) | Time from study allocation to death or last follow up. | 5 years | |
Primary | Overall survival rate of patients who receive best available non-transplant therapies (BAT) | Time from study allocation to death or last follow up. | 5 years | |
Secondary | Median change in Patient Global Impression of Change (PGIC) score | Range from -3 to 3. Positive number equals increase in quality of life. | 0 and 36 months | |
Secondary | Median change in MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) | Range from 0 to 10. Increase equals worsening of symptoms. | 0 and 36 months | |
Secondary | Median change in FACT-BMT Questionnaire | Range from 1 to 4. Increase equals increase in quality of life. | 0 and 36 months | |
Secondary | Disease-free survival of patients who receive hematopoietic stem cell transplantation (HCT) | Time from allocation to study arm to death/acute myeloid leukemia transformation or last follow up. | 5 years | |
Secondary | Disease-free survival of patients who receive best available non-transplant therapies (BAT) | Time from allocation to study arm to death/acute myeloid leukemia transformation or last follow up. | 5 years | |
Secondary | Number of patients who receive hematopoietic stem cell transplantation (HCT) in remission (complete and partial) | 3 years | ||
Secondary | Number of patients who receive best available non-transplant therapies (BAT) in remission (complete and partial) | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Not yet recruiting |
NCT06345495 -
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
|
Phase 2 | |
Terminated |
NCT04866056 -
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
|
Phase 1/Phase 2 | |
Completed |
NCT02784496 -
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
|
Phase 2 | |
Completed |
NCT00069680 -
Genetic Analysis of Gray Platelet Syndrome
|
||
Active, not recruiting |
NCT04097821 -
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06397313 -
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
|
Phase 2 | |
Not yet recruiting |
NCT06024915 -
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
|
Phase 1 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Completed |
NCT02910258 -
Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
|
||
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00997386 -
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
|
Phase 2 | |
Completed |
NCT00666549 -
Research Tissue Bank
|
||
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Terminated |
NCT00522990 -
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
|
Phase 1/Phase 2 | |
Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
Active, not recruiting |
NCT03952039 -
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
|
Phase 3 | |
Not yet recruiting |
NCT04709458 -
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
|
Phase 1 |